Olimab

Olimab is a specialized prescription biologic medication containing Denosumab ($60\text{ mg}$ in $1.0\text{ ml}$), manufactured by Intas Pharmaceuticals. Supplied as a sterile, preservative-free solution in a single-use pre-filled syringe (PFS), it is designed exclusively for subcutaneous administration. As a targeted monoclonal antibody, Olimab binds to RANKL to inhibit osteoclast formation, effectively slowing down bone breakdown. This therapeutic agent is primarily prescribed to treat osteoporosis in postmenopausal women and men at high risk for fractures, as well as to counter bone loss induced by systemic hormone ablation therapies, safely enhancing overall skeletal density.